Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Handheld diagnostics specialist genedrive confirms award of £600,000 grant

The money will be used to help fund the development of a disposable centrifuge-free plasma separation device
It is hoped the new device will be able to separate plasma without the using a centrifuge (pictured).

Handheld diagnostics specialist genedrive plc (LON:GDR) has confirmed it and its partners have been formally awarded a £600,000 grant from Innovate UK, a body which supports technology and growth businesses.

The money will be used to help fund the development of a disposable, centrifuge-free plasma separation device.

The collaboration with NHS Tayside and the University of Dundee is designed to create companion 'kit' that can be used alongside genedrive’s Hepatitis C (HCV) diagnostic “closer to a point of care setting”.

“This has the opportunity to be a very novel and impactful project and we are delighted that Innovate UK has chosen to support us,” said chief executive David Budd. 

“This device will aim to improve the applicability of the Genedrive HCV assay for closer to patient settings and would be a significant step forward in positioning the test for true decentralised diagnostics.

“Further, the device is anticipated to be independent from the Genedrive platform, opening the opportunity for other diagnostic instruments that need plasma as a starting point for blood borne viral testing."

The company said it will account for its £484,000 share of the funding as income, matched to costs incurred over the periods to 30 June 2018 and 2019.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use